Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Mylan Buys Famy Care, Licenses Lung Drug
by Lisa M. Jarvis
February 9, 2015
| A version of this story appeared in
Volume 93, Issue 6
Specialty drug company Mylan is shelling out $750 million to buy several female health care businesses from Mumbai-based Famy Care. Famy, a leader in generic oral contraceptives, has been a marketing partner of Mylan since 2008. In a separate deal, Mylan will pay Theravance Biopharma $15 million for access to TD-4208, a treatment for chronic obstructive pulmonary disease. Theravance expects to begin Phase III studies on TD-4208, a once-daily nebulized muscarinic antagonist, this year. Mylan is also taking a $30 million stake in the biotech firm.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter